These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Rahman M; Selvarajan K; Hasan MR; Chan AP; Jin C; Kim J; Chan SK; Le ND; Kim YB; Tai IT Neoplasia; 2012 Jul; 14(7):624-33. PubMed ID: 22904679 [TBL] [Abstract][Full Text] [Related]
6. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Crew TE; Elder DJ; Paraskeva C Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736 [TBL] [Abstract][Full Text] [Related]
7. c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells. Lin YM; Lu CC; Hsiang YP; Pi SC; Chen CI; Cheng KC; Pan HL; Chien PH; Chen YJ J Cell Physiol; 2019 Jul; 234(7):10336-10344. PubMed ID: 30480806 [TBL] [Abstract][Full Text] [Related]
8. Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells. Hawcroft G; Loadman PM; Belluzzi A; Hull MA Neoplasia; 2010 Aug; 12(8):618-27. PubMed ID: 20689756 [TBL] [Abstract][Full Text] [Related]
9. Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells. Qorri B; Harless W; Szewczuk MR Drug Des Devel Ther; 2020; 14():4149-4167. PubMed ID: 33116404 [TBL] [Abstract][Full Text] [Related]
10. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723 [TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells. Ganesh R; Marks DJ; Sales K; Winslet MC; Seifalian AM World J Surg Oncol; 2012 Sep; 10():200. PubMed ID: 23013454 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357 [TBL] [Abstract][Full Text] [Related]
13. Whole-Body PET Imaging in Humans Shows That Kim MJ; Anaya FJ; Manly LS; Lee JH; Hong J; Shrestha S; Telu S; Henry K; Santamaria JAM; Liow JS; Zanotti-Fregonara P; Shetty HU; Zoghbi SS; Pike VW; Innis RB J Nucl Med; 2023 Jan; 64(1):159-164. PubMed ID: 35798558 [TBL] [Abstract][Full Text] [Related]
14. Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer. Zhang Z; Ghosh A; Connolly PJ; King P; Wilde T; Wang J; Dong Y; Li X; Liao D; Chen H; Tian G; Suarez J; Bonnette WG; Pande V; Diloreto KA; Shi Y; Patel S; Pietrak B; Szewczuk L; Sensenhauser C; Dallas S; Edwards JP; Bachman KE; Evans DC J Med Chem; 2021 Aug; 64(15):11570-11596. PubMed ID: 34279934 [TBL] [Abstract][Full Text] [Related]
15. Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis. Rohwer N; Kühl AA; Ostermann AI; Hartung NM; Schebb NH; Zopf D; McDonald FM; Weylandt KH Cancer Med; 2020 Apr; 9(7):2535-2550. PubMed ID: 31994315 [TBL] [Abstract][Full Text] [Related]
16. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Schrör K Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):473-84. PubMed ID: 22122764 [TBL] [Abstract][Full Text] [Related]
17. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Yao M; Zhou W; Sangha S; Albert A; Chang AJ; Liu TC; Wolfe MM Clin Cancer Res; 2005 Feb; 11(4):1618-28. PubMed ID: 15746067 [TBL] [Abstract][Full Text] [Related]
18. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Rimon G; Sidhu RS; Lauver DA; Lee JY; Sharma NP; Yuan C; Frieler RA; Trievel RC; Lucchesi BR; Smith WL Proc Natl Acad Sci U S A; 2010 Jan; 107(1):28-33. PubMed ID: 19955429 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755 [TBL] [Abstract][Full Text] [Related]
20. [The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer]. Wang HJ; Peng ZL; Liu XQ; Yang KX; Lou JY; Luo FM Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):428-32. PubMed ID: 17593823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]